Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor alpha joining 19 (TRAJ19) is a non-functional gene segment in the T cell receptor alpha locus that encodes part of the joining (J) region in T cell receptor alpha chain gene rearrangement. While J segments are essential for generating antigen receptor diversity in T cells, the TRAJ19 segment itself is annotated as non-functional, meaning it does not typically contribute to expressed, functional T cell receptors. Therefore, TRAJ19 is not a direct therapeutic target, nor does it encode a standalone receptor or protein, but rather is a genomic sequence involved in T cell receptor gene assembly[1][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha joining 19 (non-functional) (TRAJ19).